Could a simple shot protect cancer patients from severe COVID-19?

NCT ID NCT04442048

Completed Prevention Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 17 times

Summary

This study tested whether a treatment called IMM-101 could help prevent severe respiratory infections, including COVID-19, in cancer patients who are at higher risk. About 195 people with cancer who were receiving active treatment took part. Half received IMM-101 and the other half were simply observed. The goal was to see if IMM-101 could reduce serious infections that might delay cancer care or lead to hospitalization.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHUM-Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, H2X 3E4, Canada
CIUSSS de l'Estrie - Centre hospitalier

Sherbrooke, Quebec, J1H 5N4, Canada
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
London Regional Cancer Program

London, Ontario, N6A 5W9, Canada
Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
The Research Institute of the McGill University

Montreal, Quebec, H4A 3J1, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.

CANCER COVID -19